The consequences of systemic recurrence are profound, as patients with recurrent breast cancer usually die of their disease despite second- or third-line systemic therapies [ 9, 10].
Almost all patients undergoing surgery eventually develop local or systemic recurrence [2, 3].
Although perioperative chemotherapy improves survival in patients with resectable lung cancers, systemic recurrence remains common.
However, control of distant metastases is poor, resulting in an increasing proportion of deaths from systemic recurrence.
After initial definitive treatment of prostate cancer with radical prostatectomy, brachytherapy, or external beam radiation, prostate-specific antigen (PSA) may rise due to local, regional, or systemic recurrence prior to the development of clinical symptoms.
A total of 118 MicMa patients with available information on systemic recurrence status were used to develop a prediction model using Cox-ridge regression for a gene set.
For prediction of systemic recurrence, only three out of the eleven tested gene sets achieved model convergence, which most likely contributed to a compromised combined-PI risk predictor built from insufficient signals (Figure S5A D).
For the 77 patients in the test set, the low risk group consisted of 44 patients; 14 of them had developed systemic recurrence within the follow-up time period.
Three of 12 patients developed systemic recurrence.
Seven of these 12 patients also presented a systemic recurrence.
On final diagnosis, 20 patients (32%) had a loco-regional recurrence and 36 (57%) had a systemic recurrence (14 patients had both loco-regional and systemic recurrence).
